Traws Pharma, Inc. (TRAW) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$0.37

From 52W high−88.06%

Volume98995.00

Market cap$5.63M

P/E (TTM)0.4x

P/S (TTM)2.0x

Div yield—

Key dataOct 19, 2026

Open

$0.37

From 52W high

−88.06%

Volume

98995.00

Market cap

$5.63M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

P/E (TTM)

0.4x

RSI (14)

29.2

MomentumView details →

1D Return

−0.76%

YTD Return

−66.70%

SummaryUpdated Mar 1, 2026

Traws Pharma, Inc. (NASDAQ:TRAW) is a clinical-stage biopharmaceutical company that was originally incorporated in 1998 as Onconova Therapeutics, Inc. before rebranding to its current name in April 2024. Headquartered in Newtown, Pennsylvania, the company focuses on developing small molecule oral therapies for two primary areas: respiratory viral diseases including COVID-19 and influenza, and various forms of cancer. As a clinical-stage biotech firm, Traws Pharma does not yet have approved commercial products and is currently advancing multiple drug candidates through various phases of clinical trials.

Ask drillr about Traws Pharma, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

0.4x

EV/EBITDA

−0.1x

EV/Sales

0.9x

P/S (TTM)

2.0x

P/B (TTM)

−1.1x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

328.67%

EBITDA Margin

−638.49%

ROE (TTM)

−172.66%

ROA (TTM)

112.43%

Asset Turnover

0.30x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+131.12%

EPS CAGR 3Y

+102.36%

EBITDA YoY

—

MomentumView details →

1D Return

−0.76%

YTD Return

−66.70%

1Y Return

−87.74%

RSI (14)

29.2

vs 50D SMA

−28.69%

vs 200D SMA

−69.00%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

0.43x

Quick Ratio

0.43x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.16

EPS Surprise

52.24%

Beats (12Q)

9/12

Next Q EPS Est

−$0.46

Avg Surprise (4Q)

72.42%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

2.79M

Net Income (TTM)

−19.89M

Op. CF (TTM)

−15.35M

Next earningsNov 12, 2026 →

Latest newsMore news →

Traws Pharma reported its financial results for the quarter ended June 30, 2026, and provided business highlights including updates on its lead clinical programs and its April 2026 financing.66d ago

Traws Pharma, Inc. elected Iain Dukes, Werner Cautreels, Trafford Clarke, John Leaman, and Nikolay Savchuck as directors, effective July 8, 2026.103d ago

Similar companies

Imunon, Inc.IMNN Reviva Pharmaceuticals Holdings, Inc.RVPH Creative Medical Technology Holdings, Inc.CELZ Lexaria Bioscience Corp.LEXX Evogene Ltd.EVGN Moleculin Biotech, Inc.MBRX Find similar companies →

Latest newsMore news →

Traws Pharma reported its financial results for the quarter ended June 30, 2026, and provided business highlights including updates on its lead clinical programs and its April 2026 financing.66d ago Traws Pharma, Inc. elected Iain Dukes, Werner Cautreels, Trafford Clarke, John Leaman, and Nikolay Savchuck as directors, effective July 8, 2026.103d ago Traws Pharma deferred its planned Phase 2a human influenza challenge study of tivoxavir marboxil after a negative review by the UK's Medicines and Healthcare Products Regulatory Agency.129d ago